Medicamen Biotech Ltd.
Snapshot View

600.00 +23.35 ▲4.1%

23 July 2021, 04:00:00 P.M.
Volume: 13,589

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.medicamen.com
Financial Indicators
Market Cap 743.38 Cr.
Earnings per share (EPS) 9.93 Trailing Twelve Months Ending 2021-03
Price-Earning Ratio (PE) 61.29 Trailing Twelve Months Ending 2021-03
Industry PE 35.17 Trailing Twelve Months Ending 2021-03
Book Value / Share 107.11 Trailing Twelve Months Ending 2021-03
Price to Book Value 5.68 Calculated using Price: 608.50
Dividend Yield 0.16 Period Ending 2020-03
No. of Shares Subscribed 1.22 Cr. 12,216,600 Shares
FaceValue 10
Company Profile

Medicamen Biotech Limited was incorporated in December 1993, it is a widely held, Globaly Recognized public limited company engaged in manufacturing and marketing of pharmaceutical formulations in overseas and domestic markets. Medicamen Biotech Limited is committed to produce and provide quality medicines at competitive price for domestic as well as international markets thereby being socially responsible and rendering services to the medical fraternity since inception.

Medicamen Biotech started its operation as distributor and manufacturer of medicines on loan license basis. The distribution activities were spread manifold over a wide market extending beyond the domestic market and started exporting to CIS countries.The vast distribution network with demand for low cost medicines prompted Mr. B.K. Gupta - Managing Director of the company to go for own manufacturing facilities. Thus in the later part of 1994 a land of 2,10,000 square feet in the Industrial town of Bhiwadi in the state of Rajasthan was procured.

In 1995 Medicamen Biotech Limited was enlisted in Bombay Stock Exchange and public issue was oversubscribed by more than 11 times. Within a span of 10 years Medicamen Biotech Limited is now among top 50 Indian export company.

In the year 2005 keeping the pace with the ever increasing demand and fulfilling the commitment, a second unit was installed in the Tax free zone at Haridwar in the state of Uttarakhand .The Unit II is fully operational from April 2007 with ultra modern manufacturing facilities.

Product range of the company includes:

The company is the Manufacturer and supplier of Comprehensive range of products:

  • Tablets
  • Capsules
  • Liquid Syrup
  • Dry Syrup (Beta Lactum and Non Beta Lactum)
  • Ointment
  • ORS

Achievements/ recognition:

The company is the receipents of the following certificates & awards:

  • WHO-GMP
  • ISO 9001: 2000
  • Star Export House
  • Certificate Of Merit
  • “Niryat Shree” for the four consecutive years from 2002 to 2005 from Government of India

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
+4.05%
1 Week
-0.02%
1 Month
+8.02%
3 Month
+15.71%
6 Month
+33.24%
1 Year
+53.65%
2 Year
+43.66%
5 Year
+466.57%
2 years 2019-03 2020-03
Return on Equity (%) 13.95 12.94
Return on Capital Employed (%) 19.30 16.54
Return on Assets (%) 8.80 8.36

Balance Sheet View Details

Particulars 2 years 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Shh. Funds 87 121
Non Curr. Liab. 1 4
Curr. Liab. 49 56
Minority Int.
Equity & Liab. 137 181
Non Curr. Assets 40 75
Curr. Assets 96 104
Misc. Exp. not W/O 0 2
Total Assets 137 181

Profit Loss View Details

Particulars 2 years 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Net Sales 123 126
Other Income 4 2
Total Income 126 127
Total Expenditure -105 -106
PBIDT 21 21
Interest -1 -1
Depreciation -2 -3
Taxation -6 -5
Exceptional Items
PAT 12 13

Cash Flow View Details

Particulars 2 years 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Cash Fr. Operatn. 4 13
Cash Fr. Inv. -15 -37
Cash Fr. Finan. -4 19
Net Change -14 -5
Cash & Cash Eqvt 9 3

Shareholding Pattern View Details

9 Qtrs 2019-06 (%) 2019-09 (%) 2019-12 (%) 2020-03 (%) 2020-06 (%) 2020-09 (%) 2020-12 (%) 2021-03 (%) 2021-06 (%)
Promoter 44.77 44.77 44.77 44.77 44.77 44.77 44.77 44.83 44.83
Public 55.23 55.23 55.23 55.23 55.23 55.23 55.23 55.17 55.17
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Announcements View Details

Mon, 19 Jul 2021
Shareholding for the Period Ended June 30 2021
Medicamen Biotech Ltd has submitted to BSE the Shareholding Pattern for the Period Ended June 30 2021. For more details kindly Click here
Thu, 15 Jul 2021
Statement Of Investor Complaints For The Quarter Ended June 2021
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter
0000
Name of the Signatory :- Parul Choudhary
Designation :- Company Secretary and Compliance Officer
Wed, 30 Jun 2021
Compliances-Reg.24(A)-Annual Secretarial Compliance
This is with reference to submission of Secretarial Compliance Report under regulation 24A of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 for year ended March 31 2021 and in continuation to the SEBI Circular no SEBI/HO/CFD/CMD1/P/CIR/2021/556 dated April 29 2021 please find attached Annual Secretarial Compliance Report as issued by M/s. AMJ & Associates Practicing Company Secretaries for the financial year ended March-2021.

You are requested to take the same on record.

Technical Scans View Details

Fri, 23 Jul 2021
Stock Outperforming Benchmark Index in both 1 Week and 3 Month Stock Outperforming Benchmark Index in both 1 Week and 3 Month
Stock Outperforming Sectoral Index in both 1 Week and 3 Month Stock Outperforming Sectoral Index in both 1 Week and 3 Month
Close Within 2 Year High Zone Close Within 2 Year High Zone
Both SRS And ARS Above Zero Both SRS And ARS Above Zero
+DI crossing 25 from below +DI crossing 25 from below

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 166,513.85 694.00 +1.0%
Divi's Laboratories Ltd. 128,088.59 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. 90,175.51 5,420.50 +0.7%
Cipla Ltd. 76,510.04 948.50 -0.1%
Cadila Healthcare Ltd. 62,965.29 615.05 -0.9%
Aurobindo Pharma Ltd. 56,484.48 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. 56,291.69 3,915.00 -1.8%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 57.34 694.00 +1.0%
Divi's Laboratories Ltd. Consolidated 2021-03 64.55 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 46.21 5,420.50 +0.7%
Cipla Ltd. Consolidated 2021-03 31.81 948.50 -0.1%
Cadila Healthcare Ltd. Consolidated 2021-03 29.51 615.05 -0.9%
Aurobindo Pharma Ltd. Consolidated 2021-03 10.59 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 374.38 3,915.00 -1.8%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 3.58 694.00 +1.0%
Divi's Laboratories Ltd. Consolidated 2021-03 13.78 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 5.15 5,420.50 +0.7%
Cipla Ltd. Consolidated 2021-03 4.17 948.50 -0.1%
Cadila Healthcare Ltd. Consolidated 2021-03 4.85 615.05 -0.9%
Aurobindo Pharma Ltd. Consolidated 2021-03 2.58 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 12.25 3,915.00 -1.8%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 0.18 694.00 +1.0%
Divi's Laboratories Ltd. Consolidated 2020-03 0.00 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 5,420.50 +0.7%
Cipla Ltd. Consolidated 2020-03 0.18 948.50 -0.1%
Cadila Healthcare Ltd. Consolidated 2021-03 0.35 615.05 -0.9%
Aurobindo Pharma Ltd. Consolidated 2020-03 0.33 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 1.08 3,915.00 -1.8%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 9.66 694.00 +1.0%
Divi's Laboratories Ltd. Consolidated 2020-03 19.30 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 5,420.50 +0.7%
Cipla Ltd. Consolidated 2020-03 10.09 948.50 -0.1%
Cadila Healthcare Ltd. Consolidated 2021-03 18.30 615.05 -0.9%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.53 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 13.08 3,915.00 -1.8%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 10.07 694.00 +1.0%
Divi's Laboratories Ltd. Consolidated 2020-03 25.36 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 15.24 5,420.50 +0.7%
Cipla Ltd. Consolidated 2020-03 12.53 948.50 -0.1%
Cadila Healthcare Ltd. Consolidated 2021-03 13.65 615.05 -0.9%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.80 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 17.13 3,915.00 -1.8%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 32,837.50 694.00 +1.0%
Divi's Laboratories Ltd. Consolidated 2020-03 5,394.42 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 5,420.50 +0.7%
Cipla Ltd. Consolidated 2020-03 17,131.99 948.50 -0.1%
Cadila Healthcare Ltd. Consolidated 2021-03 15,102.20 615.05 -0.9%
Aurobindo Pharma Ltd. Consolidated 2020-03 23,098.51 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 11,246.80 3,915.00 -1.8%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 4,186.79 694.00 +1.0%
Divi's Laboratories Ltd. Consolidated 2020-03 1,376.54 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 5,420.50 +0.7%
Cipla Ltd. Consolidated 2020-03 1,546.98 948.50 -0.1%
Cadila Healthcare Ltd. Consolidated 2021-03 2,137.60 615.05 -0.9%
Aurobindo Pharma Ltd. Consolidated 2020-03 2,844.69 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 434.90 3,915.00 -1.8%